Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study
Hjalmar Flygt(Uppsala University Hospital), Henrik Hjorth‐Hansen(Norwegian University of Science and Technology), Leif Stenke(Karolinska Institutet), Berit Markevärn, Satu Mustjoki(University of Helsinki), Ulla Olsson‐Strömberg(Uppsala University Hospital), Stina Söderlund(Uppsala University Hospital), Anna Lübking(Skåne University Hospital), Andreja Dimitrijevic(Odense University Hospital), Perttu Koskenvesa(Helsinki University Hospital), Arta Dreimane(Linköping University Hospital), Bjørn Tore Gjertsen(Haukeland University Hospital), Johan Richter(Skåne University Hospital), Tobias Gedde‐Dahl, Waleed Majeed(Stavanger University Hospital), Jesper Stentoft(Aarhus University Hospital), Kristina Myhr Eriksson(Sunderby sjukhus), Lene Udby(Copenhagen University Hospital)
Cited by 10
Related Papers
International nosology of heritable disorders of connective tissue, Berlin, 1986
|American Journal of Medical Genetics|1988|733
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
|Blood|2013|632
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366